What it's for (Indications)
- Mesna (2-mercaptoethane sulfonate sodium) is indicated as a prophylactic agent to reduce the incidence of hemorrhagic cystitis in patients treated with ifosfamide.
- It is also commonly used in conjunction with high-dose cyclophosphamide regimens that carry a significant risk of urotoxicity, particularly severe hemorrhagic cystitis.
- Mesna acts locally in the urinary bladder to detoxify urotoxic metabolites, specifically acrolein, that are generated during the metabolism of these oxazaphosphorine cytotoxic agents.
- Its primary role is to protect the urinary tract from chemical irritation and damage, thereby allowing the continuation of vital chemotherapy.
- This uroprotective effect is crucial for patients undergoing aggressive cancer treatment where the risk of chemotherapy-induced bladder damage could otherwise limit the effective dosing or duration of treatment.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of mesna must be carefully individualized based on the specific oxazaphosphorine chemotherapy regimen (e.g., ifosfamide or cyclophosphamide) and the patient's body surface area. Typically, mesna is administered intravenously in a dose that is 20% of the ifosfamide or cyclophosphamide dose, given at the time of chemotherapy administration and then repeated 4 and 8 hours later. This usually results in a total daily mesna dose equal to 60% of the oxazaphosphorine dose. For continuous ifosfamide infusions, mesna can be given as an initial bolus followed by a continuous infusion. Oral mesna formulations are also available, usually dosed at 40% of the oxazaphosphorine dose and given at specific intervals. It is critical to ensure adequate hydration and frequent urination to maximize the protective effect of mesna. The exact regimen should be determined by an oncology specialist experienced in chemotherapy administration. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated, mesna can cause various side effects, most of which are mild and transient.
- Common adverse reactions include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, often difficult to distinguish from those caused by the concomitant chemotherapy.
- Other frequently reported side effects involve central nervous system symptoms like headache, dizziness, and fatigue.
- Some patients may experience skin reactions such as rash, flushing, or pruritus.
- Less common but potentially more serious adverse events include hypersensitivity reactions, ranging from mild skin manifestations to severe anaphylaxis, including bronchospasm, tachycardia, and hypotension.
- Transient elevation of liver enzymes and mild leukopenia have also been reported, though causality can be challenging to ascertain due to polypharmacy.
- Urine discoloration (false positive for ketones) may also occur.
Serious Warnings
- Black Box Warning: Mesna does not have a formal FDA Black Box Warning. However, serious warnings and precautions must be considered when using this agent. **Serious Warnings:** Mesna is a uroprotective agent and is not an antineoplastic drug. It does not prevent other systemic toxicities associated with ifosfamide or cyclophosphamide, such as myelosuppression, nephrotoxicity, neurotoxicity, or cardiotoxicity. It is exclusively intended to reduce the incidence of hemorrhagic cystitis. Therefore, patients receiving ifosfamide or cyclophosphamide must still be closely monitored for all anticipated adverse effects of these cytotoxic agents. Hypersensitivity reactions, including severe anaphylactic reactions, have been reported with mesna. These reactions can manifest as rash, pruritus, urticaria, flushing, edema, bronchospasm, dyspnea, hypotension, and tachycardia. Patients should be monitored for signs and symptoms of hypersensitivity, and mesna should be immediately discontinued if such reactions occur, with appropriate medical intervention initiated. Adequate hydration and urinary output are essential for the effective uroprotection by mesna; failure to maintain these could compromise its efficacy.
- Mesna is a uroprotective agent and does not prevent other systemic toxicities associated with oxazaphosphorine chemotherapy, nor does it possess any antineoplastic activity itself.
- It is crucial to maintain adequate hydration and urinary output throughout chemotherapy and mesna administration to ensure its effectiveness.
- Patients should be monitored for signs of hypersensitivity reactions, as these can occur and may require discontinuation of mesna and supportive treatment.
- Caution should be exercised in patients with a history of allergic reactions, particularly to thiol compounds.
- Renal or hepatic impairment may affect mesna's excretion or metabolism, though dose adjustments are not typically required based on current guidelines.
- However, close monitoring is recommended.
- There is limited data on mesna use during pregnancy and lactation; it should only be used if the potential benefit justifies the potential risk to the fetus or infant.
- Mesna can also cause false-positive results in urine tests for ketones.
How it Works (Mechanism of Action)
Mesna, sodium 2-mercaptoethane sulfonate, exerts its uroprotective effect by reacting with and detoxifying the urotoxic metabolites of oxazaphosphorine chemotherapy agents, specifically acrolein, within the urinary bladder. After intravenous administration, mesna is rapidly oxidized to dimesna, its disulfide derivative, which is pharmacologically inactive. Dimesna is freely filtered by the glomeruli into the renal tubules. In the renal tubules and urinary bladder, dimesna is reduced back to the active mesna. Mesna then acts as a sulfhydryl compound, binding covalently to the double bond of acrolein, forming a stable, non-toxic thioether adduct. This reaction neutralizes the highly reactive and bladder-damaging acrolein, preventing it from irritating and damaging the urothelium, thus preventing hemorrhagic cystitis. Mesna's action is localized to the urinary tract and does not interfere with the antitumor efficacy of ifosfamide or cyclophosphamide, as it does not enter the systemic circulation in significant concentrations after being reduced back to its active form in the bladder.
Commercial Brands (Alternatives)
No other brands found for this formula.